SCHEMBL6239437

SCHEMBL6239437

O=[N+]([O-])c1ccc(-c2cccc(Cl)c2)nc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
ALDH1A1 P00352 2/20 0.53
MAPT P10636 3/20 0.53
NPBWR1 P48145 1/20 0.50
KEAP1 Q14145 1/20 0.49
NFE2L2 Q16236 1/20 0.49
KDM1A O60341 2/20 0.48
MAOB P27338 1/20 0.48
ALKBH5 Q6P6C2 1/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
LMNA P02545 1/20 0.46
PSD A5PKW4 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
IDO1 P14902 2/20 0.44
CDC25A P30304 1/20 0.42
CDC25B P30305 1/20 0.42
BCHE P06276 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6231939 0.86 RAB9A (0.60) TDP1ALDH1A1MAPTKEAP1NFE2L2
SCHEMBL14988369 0.83 NPC1 (0.50) KMT2AMEN1TDP1ALDH1A1MAPT
SCHEMBL1723569 0.82 MAPT (0.57) KMT2AMEN1ALDH1A1MAPTNPC1
SCHEMBL6237830 0.82 RAB9A (0.57) KMT2AMEN1ALDH1A1MAPTNPBWR1
SCHEMBL2130063 0.81 ALDH1A1 (0.56) KMT2AMEN1TDP1ALDH1A1MAPT
SCHEMBL2488221 0.81 ALDH1A1 (0.56) KMT2AMEN1TDP1ALDH1A1MAPT
SCHEMBL6510195 0.81 MAPT (0.54) KMT2AMEN1TDP1ALDH1A1MAPT
SCHEMBL71038 0.80 LMNA (0.54) KMT2AMEN1TDP1ALDH1A1MAPT
SCHEMBL2029610 0.79 TP53 (0.58) TDP1ALDH1A1MAPTKEAP1NFE2L2
Hydrochloric Acid SCHEMBL27598115 0.79 LMNA (0.53) KMT2AMEN1TDP1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11434245-B2 WNT pathway modulators AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2022-09-06 US disclosed
US-11434245-B2 WNT pathway modulators AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2022-09-06 US disclosed
US-20210047336-A1 WNT PATHWAY MODULATORS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2021-02-18 US disclosed
US-20210047336-A1 WNT PATHWAY MODULATORS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2021-02-18 US disclosed
US-10870653-B2 WNT pathway modulators AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2020-12-22 US disclosed
US-10870653-B2 WNT pathway modulators AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2020-12-22 US disclosed
US-20190185478-A1 WNT PATHWAY MODULATORS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2019-06-20 US disclosed
US-10189842-B2 Wnt pathway modulators AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2019-01-29 US disclosed
US-10189842-B2 Wnt pathway modulators AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2019-01-29 US disclosed
EP-3083631-B1 WNT PATHWAY MODULATORS AGENCY SCIENCE TECH & RES (SG) 2018-06-13 EP disclosed
EP-2599771-B1 NAPHTHALENE DERIVATIVE DAITO CHEMIX CORP (JP) 2016-09-14 EP disclosed
US-9206129-B2 Agent for treatment of eye diseases DAITO CHEMIX CORPORATION (JP) 2015-12-08 US disclosed
EP-2623494-B1 AGENT FOR TREATMENT OF EYE DISEASES DAITO CHEMIX CORP (JP) 2015-09-02 EP disclosed
WO-2015094119-A1 WNT PATHWAY MODULATORS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2015-06-25 WO disclosed
WO-2015094119-A1 WNT PATHWAY MODULATORS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2015-06-25 WO disclosed
US-20140148416-A1 Agent for Treatment of Eye Diseases KYOTO UNIVERSITY (JP) 2014-05-29 US disclosed
EP-2623494-A1 AGENT FOR TREATMENT OF EYE DISEASES Daito Chemix Corporation (JP) 2013-08-07 EP disclosed
US-20130184241-A1 Naphthalene Derivative KYOTO UNIVERSITY (JP) 2013-07-18 US disclosed
EP-2599771-A1 NAPHTHALENE DERIVATIVE Daito Chemix Corporation (JP) 2013-06-05 EP disclosed
WO-2005005382-A2 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INC. (US) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190185478-A1 WNT PATHWAY MODULATORS WNT1, WNT3A, WNT3 KMT2A 4155/4885MEN1 2017/4885TDP1 4060/4885
US-10189842-B2 Wnt pathway modulators WNT1, WNT3A, WNT3 KMT2A 4662/4885MEN1 4640/4885TDP1 3630/4885
US-20140148416-A1 Agent for Treatment of Eye Diseases PDE6A, ALDH1A2, PDE6D KMT2A 3649/4885MEN1 2216/4885TDP1 865/4885
US-20130184241-A1 Naphthalene Derivative VCP, NOC2L, VAT1 KMT2A 3316/4885MEN1 2693/4885TDP1 80/4885
US-11434245-B2 WNT pathway modulators WNT1, WNT3A, WNT3 KMT2A 4455/4885MEN1 2963/4885TDP1 3949/4885
US-10870653-B2 WNT pathway modulators WNT1, WNT3A, WNT3 KMT2A 4411/4885MEN1 2388/4885TDP1 4111/4885
US-20210047336-A1 WNT PATHWAY MODULATORS WNT1, WNT3A, WNT3 KMT2A 4155/4885MEN1 2017/4885TDP1 4060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.